Business Wire

SDS

Share
Raiffeisen Banking Group and Banking Technology Partner SDS Announce Joint Future Plans

The Raiffeisen Banking Group and SDS announce the signing of a multi-year cooperation agreement. The Austrian Raiffeisen Banking Group is the country's largest banking group with the most intricate network of banks and around 2.8 million retail customers in Austria. Through Raiffeisen Bank International (RBI), the group is represented in 13 markets in Central and Eastern Europe. The Austrian company SDS (Software Daten Service) is one of the leading providers of modern banking technologies in securities processing tax and compliance automation, as well as associated services in Europe. Through its owner T-Systems International, it is part of Deutsche Telekom AG.

The two companies can look back at a long and successful cooperative history. Before SDS was taken over by T-Systems International in 2004, SDS, with its flagship product SDS GEOS, was owned by RZB (Raiffeisen Zentralbank) for 11 years, which itself took over the banking software provider from Schöllerbank in 1993. During this partnership of almost 30 years, the company developed one of the most competitive solutions for automated securities and derivative processing in Europe in the form of SDS GEOS. It also established a comprehensive portfolio of internationally successful support products for tax regulation or securities compliance and a software testing division that is strongly sought after in German-speaking countries, including companies outside the banking sector.

Through the specialised subsidiaries and associated companies of the Raiffeisen Banking Group, it is possible to meet the individual needs of each customer group and to provide an all-round financial service "under one roof". For example, RBI in Austria is specialised on commercial banking and investment banking business and advises the country's top 1,000 companies as a corporate finance bank and a bank for export financing. The all-round financial service of the Raiffeisen banking group also includes financial services of Raiffeisen specialist companies such as the investment company Raiffeisen Capital Management, Raiffeisen Versicherung, Raiffeisen-Leasing or Raiffeisen Bausparkasse.

The Raiffeisen Banking Group can count on a strong, reliable, and innovative technology partner not only because of its great international market success but also to ensure future competitiveness in light of the dynamic changes in international banking. These changes are driven by growing market and consumer digitalisation, the demand for and use of artificial intelligence, disruptive market participants, and the highest efficiency and response requirements, to mention only the most important of the current challenges.

SDS Managing Director Ernst Kendlbacher comments: "We are in the middle of a digital revolution in the banking sector. Innovations in terms of creating new processes and adapting to new technologies are essential for a healthy future. Raiffeisen will continue to purchase SDS products on a large scale in the future, thus further demonstrating its confidence in our portfolio. The new contract also includes all relevant security and regulatory requirements for the Raiffeisen group. A great success for both contract partners." Edzard Janssen, Head of Group Procurement, Outsourcing, and Cost Management of Raiffeisen Bank International AG adds: "In order to be sustainably successful in competition, it is important to work with professional and innovative partners."

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye